Secreted frizzled related proteins (Sfrps) are thought to bind and regulate Wnt activity through a cysteine rich domain that is highly similar to that of Frizzled receptors. To investigate possible roles for Sfrps in chick development, we have isolated partial cDNAs encoding Sfrp-1 and Sfrp-2 and have thoroughly characterized the expression patterns of both genes. Both sfrp-1 and sfrp-2 are expressed at all stages of development analyzed, ranging from Hamburger and Hamilton stage 4 through stage 32. Expression of both sfrp-1 and sfrp-2 is observed in mesodermal and ectodermal derivatives, while sfrp-1 is also found in endodermal lineages. q
Results and discussion

Isolation of cDNAs encoding Sfrp-1 and Sfrp-2
We and others have previously reported the identi®cation and characterization of sfrp family members from a number of organisms (Ba®co et al., 1999; Baranski et al., 2000; Chang et al., 1999; Dennis et al., 1999; Duprez et al., 1999; Finch et al., 1997; Hoang et al., 1998; Hu et al., 1998; Ladher et al., 2000; Leimeister et al., 1998; Lescher et al., 1998; Leyns et al., 1997; Lin et al., 1997; Mayr et al., 1997; Melkonyan et al., 1997; Pfeffer et al., 1997; Rattner et al., 1997; Salic et al., 1997; Shirozu et al., 1996; Wada et al., 1999; Wang et al., 1997a,b; Wolf et al., 1997; Xu et al., 1998; Zhou et al., 1998) . We now report the identi®cation and characterization of partial cDNAs encoding chick Sfrp-1 and Sfrp-2.
Degenerate primers were used to amplify partial cDNAs encoding Sfrp-1 and Sfrp-2 from the total RNA of Hamburger and Hamilton stage 10 embryos by RT-PCR (Hamburger and Hamilton, 1951) . Sequencing revealed that the predicted protein sequences of Sfrp-1 and Sfrp-2 share 95 and 84% amino acid identity with their respective mouse homologues (Rattner et al., 1997) while Sfrp-2 shares 100% identity with the recently reported chick homologue (Ladher et al., 2000) .
Expression of sfrp-1 and sfrp-2 in early embryos
At streak stages of development, the two genes have overlapping patterns of expression in the presumptive neural ectoderm (Garcia-Martinez et al., 1993) , but are distinct in that sfrp-2 extends more caudally than sfrp-1 (Fig. 1) . Sfrp-1 is also found in the axial mesendoderm that ®rst emerges from the node (Fig. 1A,C,E ). This expression pattern is consistent with the later expression of sfrp-1 in the prechordal mesoderm (Figs. 2C and 3E) and notochord (Figs. 3G,I and 4F,H,J,L,N,P).
Expression of sfrp-1 and sfrp-2 in the neural tube
As development proceeds, the differences between sfrp-1 and sfrp-2 become more dramatic as sfrp-1 expression is limited to the dorsal and ventral-most cells of the anterior neural folds/neural tube ( Fig. 2A,C) while sfrp-2 is expressed along the entire A/P axis (Fig. 2B,D) . In stage 9 embryos, sfrp-2 continues to be expressed in the neural plate, neural folds and neural tube (Fig. 3C,D,F ,H,J,L). Sfrp-1, on the other hand, is expressed in the dorsal and ventral-most cells of the forebrain (Fig. 3A,B ,E). More caudally, faint expression is observed in the prospective lumenal side of the neural plate/folds (Fig. 3I,K) . As the neural plate is only one cell thick, this labeling would suggest that sfrp-1 mRNAs are localized to the apical side of individual cells. However, as this labeling is quite faint, we cannot exclude the possibility that this is an artifactual result caused by settling of the precipitate from the alkaline phosphatase reaction.
Both sfrp-1 and sfrp-2 exhibit extremely dynamic patterns of expression along both the D/V and A/P axes of the neural tube. By stage 13, sfrp-2 is expressed in the ventricular layer of the spinal cord at the level of the hindbrain (Fig. 4G) , throughout the neural tube (with two stripes of darker expression) at intermediate trunk levels (Figs. 4K, M and 5D) and throughout the neural tube (with the exception of the roofplate and the basal surface of the¯oor-plate) at caudal levels ( Fig. 4O ,Q). The striped pattern observed at the level of the trunk persists through stage 25 of development (Fig. 6F) . In contrast, sfrp-1 expression restricts to the ventral half of the neural tube, including the¯oorplate, in stage 13 embryos (Fig. 4F ,H,J,L,N,P). Although the expression in the¯oorplate remains consistent up through at least stage 18 (Fig. 5C ), the remaining stripe of expression varies, depending on the axial level and age of the embryo (Figs. 4±6) .
In cranial regions, sfrp-1 and sfrp-2 are found in the neural tube of a stage 12 embryo, with clear expression in the optic vesicle, the forebrain, the midbrain, and in alternating rhombomeres of the hindbrain (Fig. 4A±C ). Rhombomeres 1, 2, 4 and 6 are more strongly expressing than rhombomeres 3 and 5 (Fig. 4A±C) . Although the pattern is more striking with sfrp-2, we certainly observe a similar pattern for sfrp-1. As cells can be seen streaming away from the neural tube in sections of sfrp-2 labeled embryos (Fig.  4B) , this labeling may re¯ect premigratory neural crest cells. Abbreviations: dm, dermamyotome; ep, epibranchial placode; fg, foregut; kp, keel of pharynx; mes, mesencephalon; n, notochord; nc, neural crest; nt, neural tube; ol, optic lobe; ov, otic vesicle; r, rhombomere; s, somite; som, somatic mesoderm; spm, splanchic mesoderm.
Expression of sfrp-1 in the telencephalon, ventral mesencephalon, isthmus, metencephalon and rhombencephalon persists up through stage 23 (Figs. 5A and 6B ). Sfrp-2 is also expressed in the telencephelon, posterior diencephalon, mesencephalon, metencephalon, and the rhombencephalon, but in contrast to sfrp-1, it is expressed in the anterior diencephalon and is excluded from the ventral mesencephalon (Figs. 5B and 6E ). . In (G), whole-mounts were performed on neural tubes that had been dissected away from surface ectoderm. Embryos labeled with sfrp-2 in whole-mount are shown in (E) (stage 23), (H) (day 7 dorsal trunk), and (K) (day 7 hindlimb). Immunostaining of a stage 23 embryo with HNK-1 is shown in (D). For (C) (sfrp-1) and (F) (sfrp-2), a razor blade was used to cut thick sections from stage 25 embryos labeled in whole-mount. In (I), a sagittal section is shown through a stage 27 embryo that was labeled with sfrp-2. (M) (sfrp-1) and (N) (sfrp-2) show sections through (J,K), respectively. The section in (L) is a transverse section through a limb labeled with sfrp-2. In (O), the same section as shown in (L) has been immunolabeled with anti-tenascin antibodies. (P,Q,R) Show a section from the trunk of a stage 25 embryo. Labeling with sfrp-2 is shown in (P) while immunolabeling with anti-myosin antibodies is shown in (Q). The images from (P,Q) are overlaid in (R). Abbreviations: dml, dorsomedial lip of the dermamyotome; drg, dorsal root ganglia; ep, epibranchial placode; id, interdigital region; n, notochord; nc, neural crest; nt, neural tube; ov, otic vesicle; sg, sympathetic ganglia; t, tendon; vb, vertebral body; vml, ventromedial lip of the dermamyotome.
Expression in neural crest and placodes
The expression of sfrp-1 and sfrp-2 in migrating cranial neural crest cells is consistent with their expression in the rhombomeres of stage 12 1 embryos. Sfrp-1 transcripts are detected in cells positioned on either side of the otic vesicle (Fig. 4A) , which are likely to represent the neural crest contribution to cranial nerves VII±X. This expression is consistent with later expression in cranial nerves VII±X (Fig. 6A) . Sfrp-2 expression is also observed in cells that contribute to cranial ganglia, but its expression is delayed with respect to that of sfrp-1 as it is not clearly visible until stage 14 of development (Fig. 4E) . At this stage, sfrp-2 is detected in the epibranchial placodes and in migrating neural crest cells positioned on both sides of the otic vesicle (Fig. 4E) . Although sfrp-2 expression in the epibranchial placodes persists up through stage 23, it is not readily detected in cranial nerves later in development (Fig. 6E) .
Both sfrp-1 and sfrp-2 are expressed in the olfactory (Fig.  3A ,C and data not shown) and otic placodes/vesicles (Fig.  4F,G) . Expression of both genes in olfactory placodes is evident in stage 9 embryos (Fig. 3A,C) . Whereas, sfrp-2 is expressed in the otic placode in stage 10 (data not shown) and in the otic vesicle thereafter (Figs.4B,C ,E,G,5Band6E), sfrp-1 expression is not readily apparent in the otic vesicle until stage 13 (Figs. 4D,F and 5A ).
In the trunk, both sfrp-1 (Fig. 6B ) and sfrp-2 (Fig. 6E ) are expressed in a pattern that resembles that of HNK-1 (Fig. 6D ) by stage 23 of development. Whole-mounts and sections reveal that both genes are expressed in dorsal root ganglia and sympathetic ganglia (Fig. 6C,F,I ).
1.5. Expression of sfrp-1 and sfrp-2 in somites and limbs Sfrp-1 transcripts are found in axial, paraxial, intermediate and lateral mesoderm (Figs. 2±6) while sfrp-2 transcripts are consistently detected in only the paraxial mesoderm (Figs. 4±6) . In the paraxial mesoderm, sfrp-1 is expressed in segmental plate, ventral somites (Figs. 3G and 4J, L, N) and condensing vertebral bodies (Figs. 5A,C and 6B,C). Sfrp-2 is also expressed in ventral somites (Figs. 4I,K,M,O and 5D), but unlike sfrp-1, it is also expressed at slightly elevated levels in or adjacent to the myotome (Figs. 4I,K,M and 6F,H,I,P). By stage 25 of development, strong expression of sfrp-2 is observed in or around the dorsomedial and ventromedial lips of the dermamyotome (as indicated by myosin labeling; Fig. 6P±R ). Consistent with recently published data (Ladher et al., 2000) , our results suggest that sfrp-2 is expressed in cells¯anking differentiated skeletal muscle.
In the limb, both sfrp-1 and sfrp-2 are expressed in the regions surrounding the joints and between the digits (Fig.  6J±N) . Comparison of sfrp-2 expression to that of tenascin demonstrates that sfrp-2 transcripts are also found in or immediately adjacent to developing tendons (Fig. 6L,O ).
Expression in organs
Sfrp-1 and sfrp-2 transcripts are found in a number of organs and tissues. Both are expressed in the urogenital tract with sfrp-2 localized to the mesonephros (Fig. 5B ) and sfrp-1 to the developing gonad (data not shown). In addition, both sfrp-1 and sfrp-2 are expressed around the perimeter of the developing eye (Figs. 4D,E, 5A ,B and 6B,E). While sfrp-1 is found in early cardiac mesoderm (Fig. 3B) , both sfrp-1 and sfrp-2 are also found in the heart by stage 18 of development (Fig. 5) , with sfrp-1 localized to the atrium and sinus venosus and sfrp-2 localized to the ventricle and sinus venosus. The expression of sfrp-1 in many endodermally derived tissues such as the pharynx (Fig. 4H), esophagus (Fig. 5C), gut (Fig. 4J) , lung buds (data not shown) and liver (data not shown) is also consistent with the early expression of sfrp-1 (Fig. 1) .
Methods
Sfrp-1 and sfrp-2 partial cDNAs were ampli®ed by RT-PCR from total RNA isolated from stage 10 chick embryos. One set of degenerate primers resulted in the isolation of both sfrp-1 and sfrp-2 (upstream ± 5
H -GGAATTCAYGAR-ACNATGRMNGA-3 H ; downstream ± 5 H -CGGATCCTYN-ARCATNTCNGGCCA-3 H ) while a second set only resulted in the isolation of sfrp-2(upstream ± 5
H -CGAATTCATG-CCNAAYCAYYTNCAY-3 H ; downstream ± 5 H -TTACT-AGTGTNACDATNGCYTCNGG-3 H ). cDNAs were subcloned into pBluescriptKSII for subsequent sequencing. Whole-mount in situ hybridizations, cryostat sectioning, and immunolabeling were performed as previously described (Baranski et al., 2000) . Antibodies to myosin and tenascin (MF20 and M1±B4) were obtained from the Developmental Studies Hybridoma Bank (Chiquet and Fambrough, 1984; Shimizu et al., 1985) .
